Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Kim Christiansen discusses her experiences managing limited mobility and chronic pain from a partial spinal cord injury and Dr Natalie Hoff describes good physical therapy care for patients with chronic migraine headaches.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Health educators have duties to teach patient focus, motivate equity, and cultivate students’ capacity to serve our most vulnerable neighbors, wherever they reside.
AMA J Ethics. 2021;23(11):E858-863. doi:
10.1001/amajethics.2021.858.
Neurophysiological sequelae of childhood trauma can express later in the lives of patients experiencing homelessness, especially during informed consent.
AMA J Ethics. 2021;23(11):E847-851. doi:
10.1001/amajethics.2021.847.